Apr 27, 2026
Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines
Fathom Therapeutics, previously known as Atommap, has successfully raised $47 million in an oversubscribed Series A funding round, aimed at enhancing its innovative drug design capabilities through quantum chemistry and AI technologies.Led by Sutter Hill Ventures, this financing round also saw participation from several other prominent investors. Fathom's proprietary platform, Microcosmos, leverages advanced algorithms to simulate protein dynamics at an unprecedented scale, facilitating the desi